Last update: Nov. 4, 2018
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
A platelet antiaggregant indicated in the secondary prevention of thromboembolic events (after myocardial or cerebral infarction), coronary syndrome and atrial fibrillation. Administered orally in a single daily dose (EMA 2018).
Since the last update we have not found published data on its excretion in breastmilk.
Its high percentage of protein binding makes transfer to breastmilk in significant quantities unlikely. In addition, its low oral bioavailability hinders its transfer to the infant’s plasma from breastmilk, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
Used with good tolerance in pediatrics even in newborns and infants (Li 2008, Finkelstein 2005)
Several experts consider its use to probably be compatible during breastfeeding, in the event of not being able to find an alternative (Briggs 2017, Hale 2019 p 167, Rowe 2013). The risk can be minimized by waiting, if possible, a minimum of 6 hours after the last dose of the medication before breastfeeding again.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Serrano 2015, Bell 2011), especially during the neonatal period and in case of prematurity.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.